Calamos Advisors
MNTA

Calamos Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Calamos Advisors’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16,424
Closed -$547K – 761
2020
Q2 		$547K Buy
+16,424
New +$523K ﹤0.01% 678

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Calamos Advisors's MNTA Position: Q3 2020 in Review

Calamos Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 16,424 shares — an estimated $547K sold.

Calamos Advisors first reported a position in MNTA in Q2 2020 and held it in 1 quarter. The position peaked at $547K in Q2 2020. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

  • Calamos Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Calamos Advisors sold 16,424 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $547K.
  • Calamos Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Calamos Advisors's Momenta Pharmaceuticals, Inc. position peaked at $547K in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Calamos Advisors's 13F filing for Q3 2020, filed 26 Oct 2020.